北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 肝胆外科  > 期刊论文
学科主题: 临床医学
题名:
Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study
作者: Huang, Lei; Li, Guang-ming; Zhu, Ji-ye; Li, Zhao; Li, Tao; Leng, Xi-sheng
关键词: follow up ; recurrence ; targeted therapy ; chemotherapy ; survival rate ; side effect
刊名: ONCOTARGETS AND THERAPY
发表日期: 2012
DOI: 10.2147/OTT.S31387
卷: 5, 页:457-462
收录类别: SCI
文章类型: Review
WOS标题词: Science & Technology
类目[WOS]: Biotechnology & Applied Microbiology ; Oncology
研究领域[WOS]: Biotechnology & Applied Microbiology ; Oncology
关键词[WOS]: ADVANCED HEPATOCELLULAR-CARCINOMA ; THERAPY
英文摘要:

Background: The purpose of this study was to determine the efficacy of sorafenib in preventing and treating tumor recurrence after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria.

Methods: Thirty patients with primary hepatic carcinoma exceeding the Milan criteria underwent liver transplantation at our hospital between March 2008 and June 2010. Matched for age and gender, the patients were randomized to treatment with sorafenib 400 mg bid or capecitabine (control group, 1500 mg bid, administered for 2 weeks followed by a 2-week rest interval in each cycle). Treatments were discontinued 18 months after transplantation if no recurrence occurred. Patients who experienced tumor recurrence continued their allocated treatment until they were deemed no longer suitable for the medication. Sorafenib and capecitabine were stopped or their dose was reduced in patients with severe adverse reactions.

Results: The one-year recurrence rates were 53.3% and 86.6% in patients treated with sorafenib and capecitabine, respectively (chi(2) = 3.968, P < 0.05), and the one-year survival rates were 93.3% and 46.6%, respectively (chi(2) = 7.777, P < 0.05). Mean survival time was significantly longer in the sorafenib group (24.6 +/- 1.7 [range 7-28] months) than in the capecitabine group (16.4 +/- 2.7 [range 5-34], months (chi(2) = 7.154, P < 0.05). Most treatment-emergent adverse reactions in both treatment groups were of grade 1 or 2 in severity. The incidence of diarrhea and hand-foot syndrome tended to be higher in the sorafenib group.

Conclusion: For patients with primary hepatic carcinoma exceeding the Milan criteria, sorafenib may reduce or delay tumor recurrence after liver transplantation and prolong patient survival, with tolerable side effects.

语种: 英语
WOS记录号: WOS:000312481200001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/54527
Appears in Collections:北京大学第二临床医学院_肝胆外科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Ctr Hepatobiliary Surg, Peoples Hosp, Beijing 100871, Peoples R China

Recommended Citation:
Huang, Lei,Li, Guang-ming,Zhu, Ji-ye,et al. Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study[J]. ONCOTARGETS AND THERAPY,2012,5:457-462.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Huang, Lei]'s Articles
[Li, Guang-ming]'s Articles
[Zhu, Ji-ye]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Huang, Lei]‘s Articles
[Li, Guang-ming]‘s Articles
[Zhu, Ji-ye]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace